查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011177

生物製药市场：2026-2032年全球市场预测（按产品类型、技术、给药途径、治疗领域、最终用户和分销管道划分）

Biologics Market by Product Type, Technology, Route Of Administration, Therapeutic Area, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年生技药品市场价值为4,594.5亿美元，预计到2026年将成长至4,863.7亿美元，复合年增长率为6.61%，到2032年将达到7,191.7亿美元。

主要市场统计数据
基准年 2025 4594.5亿美元
预计年份：2026年 4863.7亿美元
预测年份 2032 7191.7亿美元
复合年增长率 (%) 6.61%

对当前生物製药市场趋势进行简洁且全面的概述，将科学创新、商业性挑战和经营团队重点联繫起来。

生物製药产业处于前沿科学与复杂商业性趋势的交汇点，正在重塑多个治疗领域的治疗模式。本执行摘要为负责应对短期策略环境的高阶领导者提供了清晰的叙述，整合了当前的结构性变化、监管和贸易压力、细分市场带来的机会以及区域性考量。它汇集了关于平台创新、生产和分销管道以及相关人员期望的证据，使高阶主管能够明确投资、伙伴关係和营运调整的优先顺序。

科学、监管和营运方面的整合进步如何重塑生物製药开发、生产柔软性和商业化策略。

生物製药产业正经历着一场变革性的转型，其驱动力包括技术成熟、新的法规结构以及相关人员期望的转变。基因编辑技术的进步和平台改进正将曾经的实验性方法推向更具临床可行性的领域，加速了人们对罕见疾病和复杂疾病治疗方法的关注。同时，生产模式正朝着模组化和灵活的生产能力转变，以缩短前置作业时间并提高对临床需求的应对力，从而改变整个价值链中资本配置和合作决策的标准。

本研究评估了 2025 年关税措施将如何影响生物製药利害关係人供应链中的采购、区域产能确定和筹资策略。

2025年推出的最新关税措施进一步增加了生物製药产业相关人员的复杂性，影响到跨多个司法管辖区的采购、製造地位置以及整个供应链的成本结构。针对特定原料、设备或成品生物製药的关税迫使许多企业加快重新评估筹资策略，加强与本地供应商的关係，并采取双重采购策略以降低风险。这些调整需要更精细的采购分析、重新谈判供应商合同，以及与物流合作伙伴密切合作，以确保关键试剂和组件的持续供应。

透过整合细分洞察进行策略调整，将产品模式、底层技术、给药途径、治疗领域、医疗保健环境和分销方法连结起来。

细分市场分析揭示了产品类型、技术、给药途径、治疗领域、终端用户和分销管道等方面的显着趋势，每种趋势都需要独特的策略应对措施。在产品类型方面，血液学因子、单株抗体、重组蛋白和疫苗等疗法仍然是基础生物製药类别，拥有成熟的生产和监管路径；而细胞疗法和基因疗法则正从专业机构向更广泛的商业网络发展。特别是细胞疗法，已细分为CAR-T疗法和干细胞疗法，每种疗法都有其独特的研发路径、生产限制和医疗服务模式，所有这些因素都会影响临床应用策略。

区域需求和差异化策略，旨在协调不同全球医疗保健生态系统中的生产製造、监管合作和商业化。

区域趋势正在创造独特的机会和商业挑战，这要求企业在市场准入、监管互动和生产力计画采取差异化策略。在美洲，成熟的临床生态系统和先进的製造群持续吸引对复杂治疗方法和后期研发的投资，而政策对话和支付方结构正在影响商业化进程和证据要求。在该地区营运的企业通常会优先考虑可扩展的生产结构和完善的上市后证据策略，以适应复杂的医疗服务网络和报​​销模式。

领先的生物製药公司如何将伙伴关係、模组化製造和跨职能管治相结合，以确保具有竞争力的执行力和价值交付？

主要企业的生物製药公司正透过策略伙伴关係、有针对性地投资产能以及专注于平台扩充性和合规应对力的产品组合开发，建立竞争优势。那些将自身内部能力与外部合作伙伴（例如契约製造(CMO)、学术研究机构和利基技术提供者）进行策略整合的公司，更有能力应对复杂的研发流程，并加速从实验室创新到临床应用的转化进程。投资于用于模组化生产和製程控制的先进分析技术，能够提供差异化的营运能力，从而提高批次品质的可预测性并加速技术转移。

为领导者提供可操作且优先的行动方案，以加强生物製药产业的供应链、监管合规性、生产灵活性和商业化准备。

产业领导者应优先采取一系列具体行动，以管理风险、增强韧性、加速商业化并创造临床价值。首先，将策略价值链评估纳入企业规划週期，评估采购集中度，并制定区域产能扩张和双重采购的标准。其次，在临床生命週期的早期阶段，使产品开发蓝图与监管机构和支付方的证据要求保持一致，以减少下游摩擦，并实现更灵活的商业化路径。第三，投资模组化製造平台和数位化流程控制，以缩短技术转移週期，并支援高优先级疗法的快速规模化生产。

采用多方面的调查方法，结合专家访谈、技术文献分析和营运案例审查，制定实证策略指导。

本报告整合了来自一手和二手研究的成果，采用多维度的研究方法，结合定性专家访谈、技术文献综述和案例研究，得出可靠且基于证据的结论。报告访问了研发、製造、监管事务和商业策略领域的专家，以了解他们对平台部署、生产力计画和相关人员的第一手观点。报告还查阅了二手技术文献和监管指导文件，以检验机制和合奖励的考量，并透过分析近期技术转移和供应链重组案例研究，展示了实施过程中遇到的挑战和解决方案的实际案例。

为了掌握生物製药领域的创新机会，我们整合了策略见解，强调了韧性、跨职能协调和能力投资的必要性。

生物製药产业正处于一个十字路口，科学突破与复杂的商业性现实交织在一起，既蕴藏着巨大的潜力，也面临日益增长的营运挑战。那些积极应对供应链韧性、与监管机构和支付方合作、提升生产灵活性以及以细分市场主导的商业化的企业，将更有能力将科学进步转化为对患者的切实影响和永续的商业成果。近期贸易和政策变化所带来的累积影响凸显了将地缘政治风险纳入核心策略决策的必要性。同时，基因编辑和模组化生产等技术进步正在拓展可行的治疗策略范围。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製药市场：依产品类型划分

  • 血液因子製剂
  • 细胞疗法
    • CAR-T疗法
    • 干细胞疗法
  • 基因治疗
  • 单株抗体
  • 重组蛋白
  • 疫苗

第九章：生物製药市场：依技术划分

  • 细胞培养技术
  • 基因编辑技术
    • CRISPR
    • TALENs
    • 锌指核酸酶
  • 融合瘤技术
  • 重组DNA技术

第十章：生物製药市场：依给药途径划分

  • 肌肉内部
  • 静脉
  • 皮下

第十一章：生物製药市场：依治疗领域划分

  • 自体免疫疾病
  • 心血管疾病
  • 感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学

第十二章 生物製药市场：依最终用户划分

  • 诊所
  • 家庭医疗保健
  • 医院
  • 研究机构

第十三章 生物製药市场：依通路划分

  • 医院药房
  • 线上管道
  • 零售药房

第十四章 生物製药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 生物製药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 生物製药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国生物药学市场

第十八章：中国生物製药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Catalent Inc.
  • Celltrion Inc.
  • CSL Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lonza Group AG
  • Merck & Co. Inc.
  • Moderna Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Samsung Biologics Co. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4302AC72200D

The Biologics Market was valued at USD 459.45 billion in 2025 and is projected to grow to USD 486.37 billion in 2026, with a CAGR of 6.61%, reaching USD 719.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 459.45 billion
Estimated Year [2026] USD 486.37 billion
Forecast Year [2032] USD 719.17 billion
CAGR (%) 6.61%

A concise, integrated overview of current biologics dynamics bridging scientific innovation, commercial pressure points, and operational priorities for leaders

Biologics sit at the intersection of advanced science and complex commercial dynamics, redefining treatment paradigms across multiple therapeutic areas. This executive summary synthesizes current structural shifts, regulatory and trade pressures, segmentation-driven opportunities, and regional considerations to provide a coherent narrative for senior leaders tasked with navigating the near-term strategic landscape. It brings together evidence on platform innovations, manufacturing and distribution vectors, and stakeholder expectations so that executives can prioritize investments, partnerships, and operational adjustments with clarity.

The narrative emphasizes the interplay between product innovation and the ecosystems required to deliver therapies at scale, from upstream R&D technologies through to downstream distribution channels. It highlights how changes in policy, supply chain resilience, and payer approaches are reshaping commercial pathways. By framing the key signals and practical implications, the introduction sets a foundation for reading subsequent sections as a connected set of insights intended to inform both high-level strategy and actionable initiatives within organizations active across biologics development, production, and delivery.

How convergent scientific, regulatory, and operational evolutions are reshaping biologics development, manufacturing flexibility, and commercialization strategies

The biologics landscape is undergoing transformative shifts driven by converging technological maturation, new regulatory frameworks, and evolving stakeholder expectations. Gene editing advancements and platform refinement have pushed previously experimental approaches into more clinically viable territories, accelerating interest in therapies that target rare and complex conditions. At the same time, manufacturing paradigms are shifting toward modular, flexible capacity to reduce lead times and increase responsiveness to clinical demand, altering capital allocation and partnership calculus across the value chain.

Policy and payer evolution are creating fresh incentives for outcome-based contracting and evidence generation, which in turn influence trial design, post-approval data commitments, and commercialization strategies. Digital tools and data interoperability are enhancing patient engagement and decentralized trial models, enabling more efficient recruitment and richer longitudinal evidence. Meanwhile, supply chain prioritization-spanning raw material sourcing, cold-chain logistics, and production redundancy-has become an operational imperative. These shifts collectively create both opportunities for differentiation and pressure to reconfigure traditional business models, encouraging organizations to adopt integrated cross-functional approaches that align R&D, manufacturing, regulatory affairs, and commercial planning.

Assessing how 2025 tariff measures have altered supply chain sourcing, regional capacity decisions, and procurement strategies for biologics stakeholders

Recent tariff actions instituted in 2025 introduced an additional layer of complexity for biologics stakeholders, affecting multi-jurisdictional procurement, manufacturing footprints, and cost structures across supply chains. Tariff measures that target specific inputs, equipment, or finished biologic products have prompted many organizations to reassess sourcing strategies, deepen local supplier relationships, and accelerate dual-sourcing initiatives to mitigate exposure. These adjustments have required more sophisticated procurement analytics, renegotiation of supplier contracts, and closer coordination with logistics partners to preserve continuity of critical reagent and component flows.

In response to tariff-driven uncertainties, manufacturers have also revisited capacity allocation decisions and capital investments, placing greater emphasis on regional production nodes that can serve priority markets with minimal cross-border friction. Regulatory authorities and industry groups have increasingly engaged in dialogue to clarify classification rules and to expedite customs procedures for temperature-sensitive shipments, which has eased some operational burdens. Simultaneously, payers and providers are attentive to potential downstream cost implications, prompting discussions about reimbursement frameworks and total-cost-of-care models that account for tariff effects. Ultimately, the cumulative impact of the 2025 tariff measures has elevated geopolitical considerations as a core element of strategic planning for biologics companies, influencing decisions from R&D site selection to commercialization sequencing and partnership structuring.

Integrated segmentation insights linking product modalities, enabling technologies, delivery pathways, therapeutic focuses, care settings, and distribution approaches for strategic alignment

Segment-level analysis reveals differentiated dynamics across product types, technologies, routes of administration, therapeutic areas, end users, and distribution channels, each demanding distinct strategic responses. Within product typologies, modalities such as blood factor products, monoclonal antibodies, recombinant proteins, and vaccines continue to represent foundational biologic classes with established manufacturing and regulatory pathways, while cell therapies and gene therapies are advancing from specialized centers toward broader commercial networks. Cell therapies specifically bifurcate into CAR-T therapies and stem cell therapies, each with unique development pathways, manufacturing constraints, and care-delivery models that affect clinical rollout strategies.

On the technology axis, the adoption and integration of cell culture platforms, hybridoma methods, and recombinant DNA approaches remain critical to optimizing yield and quality, whereas gene editing technology-comprising CRISPR, TALENs, and zinc finger nucleases-introduces powerful options for precision modalities but also raises new considerations around regulatory harmonization and long-term surveillance. Route-of-administration distinctions between intramuscular, intravenous, and subcutaneous delivery shape patient access strategies, cold-chain requirements, and site-of-care economics. Therapeutic area focus across autoimmune, cardiovascular diseases, infectious diseases, metabolic disorders, neurological disorders, and oncology directs clinical development prioritization and evidence generation pathways, while end users such as clinics, home healthcare services, hospitals, and research institutes determine distribution, training, and support models. Finally, distribution channel selection among hospital pharmacies, online channels, and retail pharmacies impacts fulfillment approaches, patient adherence initiatives, and the design of commercial partnerships. Taken together, these segmentation lenses provide a practical framework for aligning R&D investments, manufacturing design, and go-to-market models with the intrinsic needs of each therapeutic and delivery constellation.

Regional imperatives and differentiated strategies for aligning manufacturing, regulatory engagement, and commercialization across diverse global healthcare ecosystems

Regional dynamics are creating distinct opportunity contours and operational imperatives that require differentiated approaches to market entry, regulatory engagement, and capacity planning. In the Americas, established clinical ecosystems and advanced manufacturing clusters continue to attract investment in complex modalities and late-stage development, while policy dialogues and payer structures influence commercialization sequencing and evidence demands. Companies operating in this region frequently prioritize scalable manufacturing and robust post-market evidence strategies to align with sophisticated provider networks and reimbursement models.

Across Europe, the Middle East & Africa, stakeholders face a mix of mature regulatory frameworks in parts of Europe and capacity-constrained markets elsewhere, which encourages strategies that combine regional manufacturing hubs with tailored distribution partnerships. Regulatory harmonization efforts and shared procurement mechanisms can support wider access, but variations in infrastructure and pricing policies necessitate flexible commercial approaches. The Asia-Pacific region presents a highly heterogeneous set of conditions, with some markets offering rapid adoption pathways and growing clinical trial capacity while others focus on building manufacturing and regulatory capabilities. In many Asia-Pacific markets, favorable policy incentives and expanding healthcare demand are leading firms to accelerate technology transfer, local partnership formation, and regionally scaled production to serve both domestic and export opportunities. Across all regions, aligning manufacturing footprint, regulatory engagement, and commercialization models to local structural realities remains essential for success.

How leading biologics organizations are combining partnerships, modular manufacturing, and cross-functional governance to secure competitive execution and value delivery

Leading companies in the biologics space are consolidating their competitive positions through a blend of strategic partnerships, targeted capacity investments, and focused portfolio development that emphasizes platform scalability and regulatory readiness. Firms that strategically align their internal capabilities with external collaborators-such as CMOs, academic centers, and niche technology providers-are better positioned to manage development complexity and to accelerate translational pathways from laboratory innovations to clinical applications. Investment in modular manufacturing and advanced analytics for process control has become a distinguishing operational capability, enabling more predictable batch quality and faster tech transfer.

In parallel, successful organizations are proactively engaging regulators and payers to co-design evidence-generation strategies that demonstrate real-world value and to negotiate pathways for conditional approvals or managed-entry agreements where appropriate. Commercial sophistication is also rising, with leading players building comprehensive patient support ecosystems and innovative distribution arrangements to enhance uptake across hospitals, clinics, home care settings, and retail or online channels. Talent development and cross-functional governance structures that integrate R&D, manufacturing, regulatory affairs, and commercial teams are emerging as critical enablers for sustained execution in a landscape characterized by rapid technological change and evolving stakeholder expectations.

Practical and prioritized actions for leaders to strengthen supply chains, regulatory alignment, manufacturing agility, and commercial readiness in biologics

Industry leaders should prioritize a sequence of concrete actions designed to strengthen resilience, accelerate commercialization, and capture clinical value while managing risk. First, integrate strategic supply chain reviews into corporate planning cycles to assess sourcing concentration and to define criteria for regional capacity expansion and dual sourcing. Second, align product development roadmaps with regulatory and payer evidence requirements early in the clinical lifecycle to reduce downstream friction and to enable more flexible commercialization pathways. Third, invest in modular manufacturing platforms and digital process controls that reduce tech transfer timelines and support rapid scale-up for high-priority modalities.

In parallel, cultivate a disciplined partnership strategy that pairs internal strengths with external capabilities in advanced technologies, contract manufacturing, or specialized clinical networks, and formalize collaboration frameworks that include shared data standards and governance. Strengthen commercial models by designing distribution and patient-support programs tailored to route of administration and end-user settings, ensuring that hospital, clinic, home care, and pharmacy channels are each supported with appropriate clinical training and supply continuity measures. Finally, maintain an adaptive regulatory engagement posture to anticipate policy shifts and to participate in early dialogues on classification, approval pathways, and post-market obligations. Executing these prioritized steps will position organizations to respond more nimbly to geopolitical and technological disruptions while unlocking pathways to sustained clinical and commercial impact.

A multi-method research approach combining expert interviews, technical literature analysis, and operational case reviews to produce evidence-driven strategic guidance

This report synthesizes primary and secondary research inputs, structured around a multi-method approach that triangulates qualitative expert interviews, technical literature review, and operational case analysis to ensure robust, evidence-driven conclusions. Interviews were conducted with subject-matter experts across development, manufacturing, regulatory affairs, and commercial strategy to capture first-hand perspectives on platform adoption, capacity planning, and stakeholder incentives. Secondary technical literature and regulatory guidance documents were examined to validate mechanistic and compliance considerations, while operational case analyses of recent technology transfers and supply chain reconfigurations provided practical illustrations of execution challenges and mitigations.

Data synthesis emphasized reproducibility and traceability of sources, with analytic steps documented to support interpretation of thematic findings and implications. The methodology incorporated scenario-based sensitivity checks to test the resilience of strategic recommendations under differing policy and operational conditions. Throughout, the emphasis remained on translating empirical insights into actionable guidance for decision-makers, with transparency about evidence limitations and clear signposts for where further primary investigation would be valuable for organization-specific decisions.

Synthesis of strategic implications highlighting the need for resilience, cross-functional orchestration, and capability investments to capture biologics innovation

The biologics field is at an inflection point where scientific breakthroughs and complex commercial realities intersect, creating both significant promise and heightened operational demands. Organizations that proactively address supply chain resilience, regulatory and payer engagement, manufacturing agility, and segmentation-driven commercialization will be best positioned to translate scientific advances into patient impact and sustainable business outcomes. The cumulative effects of recent trade and policy shifts underscore the necessity of integrating geopolitical risk into core strategic decisions, while technology advances such as gene editing and modular manufacturing expand the palette of viable therapeutic strategies.

Moving forward, success will hinge on an organization's ability to orchestrate cross-functional capabilities, to form pragmatic partnerships, and to adopt evidence-centered commercialization models that reflect local regulatory and delivery contexts. Stakeholders should view the current environment as an opportunity to reconfigure traditional operating models and to invest in capabilities that support faster, more reliable delivery of complex biologics. By doing so, they can both mitigate short-term disruptions and position themselves to capture the long-term clinical and commercial benefits arising from the next wave of biologics innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Market, by Product Type

  • 8.1. Blood Factor Products
  • 8.2. Cell Therapies
    • 8.2.1. CAR-T Therapies
    • 8.2.2. Stem Cell Therapy
  • 8.3. Gene Therapies
  • 8.4. Monoclonal Antibodies
  • 8.5. Recombinant Proteins
  • 8.6. Vaccines

9. Biologics Market, by Technology

  • 9.1. Cell Culture Technology
  • 9.2. Gene Editing Technology
    • 9.2.1. CRISPR
    • 9.2.2. TALENs
    • 9.2.3. Zinc Finger Nucleases
  • 9.3. Hybridoma Technology
  • 9.4. Recombinant DNA Technology

10. Biologics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Biologics Market, by Therapeutic Area

  • 11.1. Autoimmune
  • 11.2. Cardiovascular Diseases
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Oncology

12. Biologics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Biologics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Channel
  • 13.3. Retail Pharmacy

14. Biologics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biologics Market

18. China Biologics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. Biogen Inc.
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Catalent Inc.
  • 19.13. Celltrion Inc.
  • 19.14. CSL Limited
  • 19.15. Eli Lilly and Company
  • 19.16. Gilead Sciences Inc.
  • 19.17. GlaxoSmithKline plc
  • 19.18. Johnson & Johnson
  • 19.19. Lonza Group AG
  • 19.20. Merck & Co. Inc.
  • 19.21. Moderna Inc.
  • 19.22. Novartis AG
  • 19.23. Novo Nordisk A/S
  • 19.24. Pfizer Inc.
  • 19.25. Roche Holding AG
  • 19.26. Samsung Biologics Co. Ltd.
  • 19.27. Sanofi SA
  • 19.28. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)